A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered Via a SelfDose (TM) Device in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis
收藏DataCite Commons2025-05-21 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008338/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics,
immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in
participants with moderate to severe plaque-type psoriasis.
提供机构：
Vivli
创建时间：
2022-08-12
